<DOC>
	<DOCNO>NCT02583412</DOCNO>
	<brief_summary>The overall aim study determine accelerate `` BexseroÂ® ( Multicomponent meningococcal B vaccine ) '' schedule compare standard schedule immunogenic , safe , tolerable , order increase capacity rapid outbreak control . In pilot study formal hypothesis test .</brief_summary>
	<brief_title>Pilot Study Immunogenicity , Reactogenicity Tolerability Two Schedules 4CmenB Vaccine Adolescents Young Adults</brief_title>
	<detailed_description>A pilot study evaluate feasibility rapid clinical trial time meningococcal B outbreak , compare accelerate schedule 4CMen B ( 0 , 3 week ) 0 , 2 month schedule , determine compress schedule immunogenic , safe tolerable . A shorter schedule offer potential benefit rapid direct indirect protection , use few public health resource implementation .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Participant willing able give inform consent participation trial . Male Female , age 17 25 year . Current intend student educational setting 20152016 year . Female participant child bear potential male participant whose partner child bear potential must willing ensure partner use effective contraception study . In Investigator 's opinion , able willing comply trial requirement . Significant renal hepatic impairment . Any significant disease disorder , opinion Investigator , may either put participant risk participation trial , may influence result trial , participant 's ability participate trial . Participant another research trial involve investigational product medical device prior 12 week . Previous bacteriologically confirm N. meningitidis disease . Prior receipt meningococcal B vaccine Hypersensitivity vaccine component product use study ( see product monograph ) Immunodeficiency autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>